Source: Endpoints News

Merck: Merck details injectable Keytruda data as it awaits FDA decision

Merck shared Phase 3 data showing that an injectable version of its blockbuster cancer drug Keytruda is comparable to the approved intravenous infusion in lung cancer patients. And it said it' ...

Read full article »
Annual Revenue
$50-100B
Employees
50-100K
Robert M. Davis's photo - Chairman & CEO of Merck

Chairman & CEO

Robert M. Davis

CEO Approval Rating

78/100

Read more